Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib vs Cetuximab in HNSCC
NCT00514943Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2007
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Boehringer Ingelheim. Started Aug 2007; status: completed.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00514943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00514943.